Anzeige
Mehr »
Login
Samstag, 02.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Technischer Ausbruch: Diese Kupferaktie ist in den letzten 52 Wochen um 300 % gestiegen! Der Durchbruch läuft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 879430 | ISIN: US7194051022 | Ticker-Symbol: PQ2
Tradegate
01.11.24
17:20 Uhr
21,540 Euro
+0,140
+0,65 %
1-Jahres-Chart
PHOTRONICS INC Chart 1 Jahr
5-Tage-Chart
PHOTRONICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
21,01021,61013:05
21,33021,46001.11.
GlobeNewswire (Europe)
189 Leser
Artikel bewerten:
(1)

Photronics, Inc.: Photronics Reports Third Quarter Fiscal 2024 Results and Share Repurchase Authorization

BROOKFIELD, Conn., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Photronics, Inc. (NASDAQ:PLAB), a worldwide leader in photomask technologies and solutions, today reported financial results for its third quarter of fiscal year 2024 ended July 28, 2024.

"Market softness in some segments during the quarter impacted photomask demand, reducing both IC and FPD revenue," said Frank Lee, chief executive officer. "The photomask demand recovery that started to take shape early in the third quarter slowed during the period due to select regional and end-use customer order patterns. This was combined with broader customer focus on rising semiconductor channel inventory that limited chip design activity through the quarter. In response, we tuned our mix and sales strategy, allowing us to optimize margins despite lower demand. Megatrends such as AI, supply chain regionalization, and edge computing are driving secular photomask value and demand, supporting our optimistic view of the long-term global photomask industry outlook. Our leadership position gives us confidence we can drive future margins while at the same time execute smart investment and deployment strategies that can deliver top line growth and shareholder value."

Third Quarter Fiscal 2024 Results

  • Revenue was $211.0 million, down 6% year-over-year and 3% sequentially.
  • GAAP Net income attributable to Photronics, Inc. shareholders was $34.4 million, or $0.55 per diluted share, compared with $27.0 million, or $0.44 per diluted share in the third quarter of 2023 and $36.3 million, or $0.58 per diluted share in the second quarter of 2024.
  • Non-GAAP Net income attributable to Photronics, Inc. shareholders was $32.0 million, or $0.51 per diluted share, compared with $31.6 million, or $0.51 per diluted share in the third quarter of 2023 and $28.7 million, or $0.46 per diluted share in the second quarter of 2024.
  • IC revenue was $155.9 million, down 4% year-over-year and 3% sequentially.
  • FPD revenue was $55.1 million, down 10% from the same quarter last year and 2% sequentially.
  • Cash generated from operating activities was $75.1 million, and cash invested in organic growth through capital expenditures was $24.4 million.
  • Cash and Short-term investments at the end of the quarter were $606.4 million, and Debt was $20.1 million.

Share Repurchase

In addition, the Board of Directors has authorized an increase of the Company's existing share repurchase program from the $31.7 million remaining up to a total of $100 million of its common stock. Any purchases will occur pursuant to a repurchase plan under SEC Rule 10b5-1.

"This announcement is a testament to our ability to generate strong cash flows and maintain a solid balance sheet over various economic conditions," continued Dr. Lee. "We are taking this step to demonstrate our commitment to enhancing shareholder returns by returning cash to our shareholders and investing in the value we see in our equity."

This authorization does not obligate the Company to repurchase any dollar amount or number of shares of common stock. The repurchase program may be suspended or discontinued at any time.

Fourth Quarter Fiscal 2024 Guidance

For the fourth quarter of fiscal 2024, Photronics expects Revenue to be between $213 million and $221 million and non-GAAP Net income attributable to Photronics, Inc. shareholders to be between $0.48 and $0.54 per diluted share.

Webcast

A webcast to discuss these results is scheduled for 8:30 a.m. Eastern time on Thursday, August 29, 2024. The call will be broadcast live and on-demand on the Events and Presentations link on the Photronics website. Analysts and investors who wish to participate in the Q&A portion of the call should click here. It is suggested that participants register fifteen minutes prior to the call's scheduled start time.

About Photronics

Photronics is a leading worldwide manufacturer of integrated circuit (IC) and flat panel display (FPD) photomasks. High precision quartz plates that contain microscopic images of electronic circuits, photomasks are a key element in the IC and FPD manufacturing process. Founded in 1969, Photronics has been a trusted photomask supplier for over 50 years. As of October 31, 2023, the company had approximately 1,885 employees. The company operates 11 strategically located manufacturing facilities in Asia, Europe, and North America. Additional information on the company can be accessed at www.photronics.com.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" regarding our industry, our strategic position, and our financial and operating results. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results, performance or achievements to differ materially. Please refer to the documents we file with the Securities and Exchange Commission. These documents contain and identify important factors that could cause our actual results to differ materially from those contained in these forward-looking statements. These certain factors can be found in our most recent SEC filings. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. We are under no duty to update any of the forward-looking statements after the date of this release to conform these statements to actual results.

Non-GAAP Financial Measures

Non-GAAP Net Income attributable to Photronics, Inc. shareholders and non-GAAP earnings per share are "non-GAAP financial measures" as such term is defined by Regulation G of the Securities and Exchange Commission, and may differ from similarly named non-GAAP financial measures used by other companies. The attached financial supplement reconciles Photronics, Inc. financial results under GAAP to non-GAAP financial information. We believe these non-GAAP financial measures that exclude certain items are useful for analysts and investors to evaluate our future on-going performance because they enable a more meaningful comparison of our projected performance with our historical results. These non-GAAP metrics are not a measure of consolidated operating results under U.S. GAAP and should not be considered as an alternative to Net income (loss), Net income (loss) per share, or any other measure of consolidated results under U.S. GAAP. The items excluded from these non-GAAP metrics, but included in the calculation of their closest GAAP equivalent, are significant components of the condensed consolidated statement of income and must be considered in performing a comprehensive assessment of overall financial performance. Please refer to the non-GAAP reconciliations below.

PHOTRONICS, INC.
Condensed Consolidated Statements of Income
(in thousands, except per share amounts)
(Unaudited)
Three Months Ended Nine Months Ended
July 28, April 28, July 30, July 28, July 30,
2024 2024 2023
2024 2023
Revenue $210,984 $217,000 $224,206 $644,318 $664,603
Cost of goods sold 135,846 137,749 137,405 410,674 413,323
Gross Profit 75,138 79,251 86,801 233,644 251,280
Operating Expenses:
Selling, general and administrative 19,436 18,996 18,032 56,753 52,728
Research and development 3,555 4,292 3,505 11,291 10,287
Total Operating Expenses 22,991 23,288 21,537 68,044 63,015
Other operating gain 1 89 - 90 -
Operating Income 52,148 56,052 65,264 165,690 188,265
Non-operating (loss) income, net 10,145 20,534 (911) 26,931 (1,764)
Income Before Income Tax Provision 62,293 76,586 64,353 192,621 186,501
Income tax provision 14,124 20,214 16,098 48,998 50,023
Net Income 48,169 56,372 48,255 143,623 136,478
Net income attributable to noncontrolling interests 13,781 20,121 21,296 46,804 55,604
Net income attributable to Photronics, Inc. shareholders$34,388 $36,251 $26,959 $96,819 $80,874
Earnings per share:
Basic $0.56 $0.59 $0.44 $1.57 $1.32
Diluted $0.55 $0.58 $0.44 $1.55 $1.31
Weighted-average number of common shares outstanding:
Basic 61,815 61,771 61,233 61,681 61,089
Diluted 62,414 62,409 61,974 62,369 61,650
PHOTRONICS, INC.
Condensed Consolidated Balance Sheets
(in thousands)
(Unaudited)
July 28, October 31,
2024 2023
Assets
Current assets:
Cash and cash equivalents $537,331 $499,292
Short-term investments 69,046 12,915
Accounts receivable 199,926 194,927
Inventories 55,472 49,963
Other current assets 30,865 28,353
Total current assets 892,640 785,450
Property, plant and equipment, net 722,638 709,244
Other assets 29,823 31,527
Total assets $1,645,101 $1,526,221
Liabilities and Equity
Current liabilities:
Current portion of long-term debt$20,090 $6,621
Accounts payable and accrued liabilities 171,036 178,602
Total current liabilities 191,126 185,223
Long-term debt 28 17,998
Other liabilities 40,518 47,391
Equity:
Photronics, Inc. shareholders' equity 1,067,994 975,008
Noncontrolling interests 345,435 300,601
Total equity 1,413,429 1,275,609
Total liabilities and equity $1,645,101 $1,526,221
PHOTRONICS, INC.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(Unaudited)
Nine Months Ended
July 28, July 30,
2024
2023
Cash flows from operating activities:
Net income $143,623 $136,478
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation and amortization 61,613 59,523
Share-based compensation 9,841 5,874
Changes in operating assets, liabilities and other (22,003) (6,319)
Net cash provided by operating activities 193,074 195,556
Cash flows from investing activities:
Purchases of property, plant and equipment (87,733) (78,813)
Purchases of short-term investments (100,558) (9,837)
Proceeds from maturities of short-term investments 44,696 22,500
Government incentives 1,541 2,033
Other (4) (116)
Net cash used in investing activities (142,058) (64,233)
Cash flows from financing activities:
Repayments of debt (4,500) (16,351)
Proceeds from share-based arrangements 1,074 1,241
Net settlements of restricted stock awards (3,002) (1,292)
Net cash used in financing activities (6,428) (16,402)
Effects of exchange rate changes on cash, cash equivalents, and restricted cash (6,454) 13,813
Net increase in cash, cash equivalents, and restricted cash 38,134 128,734
Cash, cash equivalents, and restricted cash, beginning of period 501,867 322,409
Cash, cash equivalents, and restricted cash, end of period$540,001 $451,143
PHOTRONICS, INC.
Reconciliation of GAAP Net income attributable to Photronics, Inc. shareholders to Non-GAAP Net income
(in thousands)
(Unaudited)
Three Months ended
July 28, April 28, July 30,
2024
2024
2023
GAAP Net income attributable to Photronics, Inc. shareholders$34,388 $36,251 $26,959
FX (gain) loss (4,068) (14,766) 4,543
Estimated tax effects of FX (gain) loss 914 3,743 (1,193)
Estimated noncontrolling interest effects of above 681 3,489 1,328
Non-GAAP Net income attributable to Photronics, Inc. shareholders$31,915 $28,717 $31,637
Weighted-average number of common shares outstanding - Diluted 62,414 62,409 61,974
GAAP Diluted earnings per share$0.55 $0.58 $0.44
Effects of non-GAAP adjustments above (0.04) (0.12) 0.07
Non-GAAP Diluted earnings per share$0.51 $0.46 $0.51

For Further Information:
Eric Rivera
Chief Financial Officer
203.740.5301
investorrelations@photronics.com


© 2024 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.